Acomplia

Acomplia (Rimonabant) is the first-in-class CB1 blocker approved for use in patients with overweight or obese in the presence of concomitant risk factors such as diabetes mellitus type 2 or dyslipidemy.

In clinical studies, there have been proved encouraging results when of using Acomplia. During two years of the study, participants have not only lost an average 8.7kg of body weight but also improve their cardiovascular profile. According to experts, Acomplia does not provide “emergency break”, but it opens up a new mechanism of action, which joined the arsenal of physicians, allowing them to use many ways to treat obesity.

The correct intake of Acomplia can help patients to get rid of excess weight without side effects and unwanted consequences, like fast weigh gaining. But patients should remember, that Acomplia is not a panacea for obesity – it’s only a little step in long way of fighting with fat. In order to obtain maximum effect from treatment with Acomplia, patients should follow some diet and engage in physical activity. Only combining Acomplia, sport and diet – you can reach amazing results and improve your overall health condition!